FDG-PET in Advanced Melanoma
NCT02236546 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 3
Last updated 2017-04-13
Summary
This clinical trial studies how well FDG-PET/CT measures early response in patients with stage III-IV melanoma who are receiving chemotherapy. Positron emission tomography (PET)/computed tomography (CT) uses a metabolic imaging radiotracer, \[18F\]fluorodeoxyglucose (FDG), which selectively accumulates in tumors. FDG-PET/CT of advanced melanoma before, during, and after treatment may improve methods for predicting which patients may benefit from therapy.
Conditions
- Recurrent Melanoma
- Stage IIIA Melanoma
- Stage IIIB Melanoma
- Stage IIIC Melanoma
- Stage IV Melanoma
Interventions
- DIAGNOSTIC_TEST
-
[18F]fluorodeoxyglucose
FDG is administered intravenously approximately 60 minutes prior to the start of PET image acquisition.
- OTHER
-
Molecular assays on biopsied tissue
Correlative studies
- DEVICE
-
positron emission tomography
Undergo FDG-PET/CT
- DEVICE
-
computed tomography
CT that is part of FDG-PET/CT is a low-milliampere, low-resolution scan that is used for anatomic localization and attenuation correction for PET images.
Sponsors & Collaborators
-
National Cancer Institute (NCI)
collaborator NIH -
Vanderbilt-Ingram Cancer Center
lead OTHER
Principal Investigators
-
Tom Yankeelov, PhD · Vanderbilt-Ingram Cancer Center
Study Design
- Allocation
- NA
- Purpose
- DIAGNOSTIC
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2012-05-31
- Primary Completion
- 2014-10-31
- Completion
- 2015-11-30
Countries
- United States
Study Locations
More Related Trials
-
Serial [18F]Fluorodeoxyglucose ([18F]FDG )PET/CT as a Biomarker of Therapeutic Response in Anti-PD1/PDL1 Therapy
NCT02608528 ·Status: TERMINATED
-
PET Imaging of Patients With Melanoma and Malignant Brain Tumors Using an 124I-labeled cRGDY Silica Nanomolecular Particle Tracer: A Microdosing Study
NCT01266096 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
PET Study in Patients With Non-Hodgkin Lymphoma
NCT00712556 ·Status: COMPLETED
-
18F-FSPG PET/CT for Cancer Patients on Therapy
NCT02599194 ·Status: COMPLETED ·Phase: PHASE2
-
Fludeoxyglucose F 18 PET/CT Scans in Predicting Therapy Response in Patients With Stage IIIA Non-Small Cell Lung Cancer Undergoing Chemoradiation
NCT01314677 ·Status: WITHDRAWN ·Phase: NA
-
Serial [18F]Thymidine (FLT)PET/CT as a Biomarker of Response in Pemetrexed Therapy for Non-Small Cell Lung Cancer
NCT02274038 ·Status: TERMINATED ·Phase: NA
-
MRI and PET to Assess Pembrolizumab Response
NCT02591654 ·Status: TERMINATED ·Phase: EARLY_PHASE1
-
PET-CT in the Management of Patients With Stage III or IV Metastatic Melanoma
NCT00828126 ·Status: COMPLETED
-
Imaging of T-cell Activation With [18F]F-AraG in Advanced Non Small Cell Lung Cancer
NCT04726215 ·Status: UNKNOWN ·Phase: PHASE2
-
Positron Emission Tomography in Predicting Response in Patients Who Are Undergoing Treatment With Pemetrexed Disodium and Cisplatin With or Without Surgery for Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer
NCT00227539 ·Status: COMPLETED ·Phase: PHASE2
-
PET-DECT for Staging and Imaged Based Radiotherapy Planning in Lung Cancer
NCT03146117 ·Status: TERMINATED
-
Gene Expression and FDG PET/MRI in Evaluating Treatment Response in Patients With Locally Advanced Rectal Cancer Undergoing Chemotherapy and Radiation Therapy Before Surgery
NCT02112162 ·Status: TERMINATED ·Phase: PHASE1
-
Improving Clinical PET/CT Image Quality in Retrospectively Reconstructed Breath-Hold Images
NCT01109953 ·Status: TERMINATED
-
Fludeoxyglucose F18 Positron Emission Tomography Imaging In Assessing Patients Before and After Treatment for Locally Advanced Non-Small Cell Lung Cancer
NCT00083083 ·Status: UNKNOWN ·Phase: PHASE2
-
PET and/or MRI Scans in Assessing Tumor Response in Patients Receiving Antiangiogenesis Therapy
NCT00019565 ·Status: COMPLETED ·Phase: PHASE1
-
A Pilot Study Treatment of Malignant Tumors Using [18F] Fluorodeoxyglucose (FDG)
NCT02130492 ·Status: SUSPENDED ·Phase: PHASE1/PHASE2
-
PET Scan in Patients With Lung and Esophageal Cancers That May Be Removed by Surgery
NCT00002930 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Serial FLT PET Imaging in Cancer Patients for Monitoring of Response to Therapy
NCT02139150 ·Status: WITHDRAWN ·Phase: NA
-
PET Imaging With [18F]F-AraG in Advanced Non-small Cell Lung Cancer (NSCLC)
NCT04524195 ·Status: TERMINATED ·Phase: PHASE1
-
Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF
NCT03604315 ·Status: RECRUITING ·Phase: PHASE1
-
18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
NCT01806675 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
FLT-PET/MRI for Early Response Monitoring to Novel Cancer Therapeutic Agents
NCT02055586 ·Status: COMPLETED
-
PET/CT Evaluation of Treatment Response in Breast Cancer
NCT01222416 ·Status: TERMINATED ·Phase: NA
-
Pilot Study to Evaluate 18F-fluorodeoxyglucose (FDG) Positron Emission Tomography /Computed Tomography (PET/CT) in Prediction of Early Response to Chemotherapy in Ovarian Cancer.
NCT00620243 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Fluorothymidine F-18 PET in Diagnosing Patients With Intermediate or High Grade Soft Tissue Sarcoma
NCT03613259 ·Status: WITHDRAWN ·Phase: EARLY_PHASE1